Increasing Launch Of Platform To Accelerate Peptide Drug Discovery Research is driving the Global Peptides Market, are expected to drive market expansion in the near future at a CAGR of 7.11% during the forecast period 2024 to 2035

Market Research Future (MRFR) has published a cooked research report on the “Global Peptides Market” that contains information from 2019 to 2035.

The Global Peptides Market is estimated to register a CAGR of 7.11% during the forecast period of 2024 to 2035.

MRFR recognizes the following companies as the key players in the Global Peptides Market— AMGEN INC., ELI LILLY AND COMPANY, PFIZER INC., SUN PHARMACEUTICAL INDUSTRIES LTD., MERCK KGAA, TAKEDA PHARMACEUTICAL COMPANY LIMITED, ASTRAZENECA, NOVARTIS AG, SANOFI, IRONWOOD PHARMACEUTICALS, INC., among others.

Market Highlights

The Global Peptides Market is estimated to register a CAGR of 7.11% during the forecast period and is estimated to reach USD 97.18 Billion by 2035.

The growing awareness of peptide-based therapeutics is significantly boosting the global market for peptide drugs, as more healthcare professionals and patients recognize their potential in treating a variety of conditions, including cancer, diabetes, and autoimmune disorders. As peptides are increasingly understood for their specificity and reduced side effects compared to traditional small molecule drugs, demand for these innovative therapies is surging. Enhanced research and development efforts, alongside successful clinical trials showcasing their efficacy, are further driving interest and investment in peptide therapeutics. Furthermore, peptide drugs present several key advantages over small molecules, primarily characterized by heightened target specificity and potency, often demonstrated by EC50 values in the nanomolar range or lower. This increased specificity leads to fewer side effects, as peptide therapeutics are less likely to interact with unintended biological targets. 

The inherent diversity of side chains in peptides enables a broad spectrum of potential targets, enhancing their therapeutic versatility. Additionally, peptides tend to exhibit more predictable metabolic profiles compared to small molecules, with their metabolites generally being non-toxic. Furthermore, metabolic interactions, such as those involving cytochrome P450 (CYP) inhibition, are less common with peptides, contributing to a safer overall therapeutic profile. These advantages position peptide drugs as a compelling option in the landscape of modern therapeutics. Additionally, advances in peptide synthesis and delivery methods are making these treatments more accessible and cost-effective, fueling their adoption in clinical practice. This heightened awareness and the expanding range of therapeutic applications are positioning the peptide drugs market for robust growth in the coming years.

Access full report @ https://www.marketresearchfuture.com/reports/peptides-market-56161

Segment Analysis

The Global Peptides Market has been segmented based By Route Of Administration, By Age Group, By Indication, By Distribution Channel

Based on Route of Administration, the Global Peptides Market has been bifurcated into Oral and Parenteral. Parenteral is further segmented into Intravenous, Subcutaneous, and Intramuscular. The parenteral segment held the largest market share in 2024, and the oral segment is the fastest-growing segment during the forecast period (2024-2035)

The oral route has gained traction due to its non-invasive nature, making it more convenient for patients, particularly for chronic diseases requiring long-term therapy. According to the Centre for Diseases Control and Prevention in 2019, the prevalence of chronic diseases in adults was around 60% globally, and it is reportedly much higher among elderly people. It is estimated that about 70% of adults will die of one or more chronic diseases. The rising prevalence of cancer, cardiovascular disorders, diabetes, Parkinson's disease, and other conditions demands oral medications.

Based on Age Group, the Global Peptides Market has been bifurcated into Pediatrics and Adult. The adult segment held the largest market in 2024, and the pediatric segment is the fastest growing segment during the forecast period.

In the Pediatrics segment, the incidence of pediatric diseases has been on the rise with diseases such as diabetes, growth hormone deficiencies, and rare genetic disorders. Ensuring better outcomes for the future generation around the globe has become a goal and priority among governments and healthcare organizations when it comes to advanced treatments like peptide therapy. Pediatric preparations of peptide drugs are designed to be sensitive to the diverse metabolic and physiological needs of children and thereby increase the scope for clinical trials and investments in R&D. The incidence of pediatric diabetes is on the rise not only in developing nations but also in well-developed nations like the US and Europe, due to which there is an increased effort in developing child-friendly peptide-based treatments for glycemic control. According to global health statistics, the incidence of pediatric endocrine disorders has been gradually increasing over the last decade. This further increases the demand for innovative therapies.

Based on Indication, the Global Peptides Market has been segmented into Diabetes Mellitus, Obesity, Short Bowel Syndrome (SBS), Human Growth Hormone (hGH) Deficiency, Hemophilia, Acromegaly, Hypoparathyroidism, Cancer, Neurological disorders, Cardiovascular Disorders, and Others. Human Growth Hormone (hGH) Deficiency is further bifurcated into Pediatrics and Adult. The diabetes mellitus segment held the largest market in 2023, and the human growth hormone (HGH) segment is the fastest growing segment during the forecast period.

Diabetes Mellitus is one of the primary drivers for the peptide market due to the rising global incidence of diabetes. According to the International Diabetes Federation (IDF), in 2021, approximately 537 billion people worldwide were living with diabetes, and this number is expected to soar to 643 billion by 2030. Similarly, according to the American Diabetes Association, diabetes affected 38.4 billion Americans, or 11.6% of the population, in 2021. Type 1 diabetes affects around 2.0 billion Americans, including approximately 304,000 children and adolescents. The growing adoption of peptide-based therapies, particularly GLP-1 receptor agonists such as Liraglutide and Semaglutide, is playing a critical role in improving glycemic control and reducing the risk of cardiovascular complications in diabetic patients. Governments in regions like the US, Europe, and Asia-Pacific are increasing healthcare expenditure to manage the diabetes burden, thereby promoting the use of innovative peptide therapies.

Based on Distribution Channel, the Global Peptides Market has been segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The hospital pharmacies segment held the largest market in 2023, and the online pharmacies segment is the fastest growing segment during the forecast period.

Due to increased prescription of peptide-based drugs in critical and complex conditions such as diabetes, and cardiovascular diseases among others, drug therapy in hospitals forms a vast market. Hospitals are centers that have the sole responsibility of carrying out peptide therapy, especially for critical care and specialized treatments. The world is witnessing an increase in hospital admissions with chronic diseases. With the availability of advanced peptide drugs on the hospitals, this segment is experiencing a boost in demand. The hospitals are not only working on the infrastructure of hospitals but are also upgrading the therapeutics available to patients, which include access to peptides, further fueling the market.

Regional Analysis

Based on region, the Global Peptide Market has been segmented into North America, Europe, Asia-Pacific, and Rest of the World. North America accounted for the largest market share in 2023 and is anticipated to reach USD 31.58 billion by 2035. However, Asia-Pacific is projected to grow at the highest CAGR during the forecast period.

North America is further segmented into the US, & Canada. The peptides market in North America is thriving, characterized by a dynamic interplay of innovation and demand. This growth is primarily fueled by the increasing prevalence of chronic diseases, such as cancer, diabetes, and cardiovascular disorders, which drives the need for effective peptide-based therapeutics. According to the US Department of Health and Human Services, around 129 billion people in the US have at least one significant chronic disease (for example, heart disease, cancer, diabetes, obesity, or hypertension). Five of the top ten main causes of death in the United States are either preventable or closely connected with chronic conditions that can be treated. Over the last two decades, prevalence has steadily climbed, and this pattern is projected to continue. An increasing proportion of Americans suffer from several chronic illnesses; 42% have two or more, and 12% have at least five. Aside from the personal effects, chronic sickness has a significant influence on the US healthcare system. Approximately 90% of the $4.1 trillion spent on health care each year goes toward managing and treating mental health issues and chronic illnesses. On the other hand, according to Statistique Canada, in 2021, 45.1% of Canadians had at least one serious chronic illness. In 2021, around 2.5 billion Canadians reported having unmet medical needs.

The Asia-Pacific Peptide Market is projected to grow at a CAGR of 8.42% during the forecast period. Asia-Pacific is further segmented into the China, India, Japan, South Korea, Australia, and Rest of Asia-pacific.

The peptide market in the Asia-Pacific region is undergoing remarkable growth, fueled by a multifaceted array of drivers that are shaping its landscape. One of the most significant factors is the rising incidence of chronic diseases, including diabetes, cancer, and cardiovascular conditions. For instance, According to National Institute of Health, over 60% of diabetics living in Asia, with China and India accounting for nearly half of the total. More than 138.2 billion people in the Western Pacific, the most populated region in the globe, have diabetes, and by 2035, that figure might reach 201.8 billion. As these health challenges become more prevalent, the demand for effective peptide-based therapeutics is surging, prompting healthcare providers to seek innovative treatment options

Key Findings of the Study

• The Global Peptides Market is expected to reach USD 97.18 Billion by 2035, at a CAGR of 7.11% during the forecast period.


• The Asia Pacific region accounted for the fastest growing in the global market.


• Based on Indication, the Diabetes Mellitus segment was attributed to holding the largest market in 2023.


• AMGEN INC., ELI LILLY AND COMPANY, PFIZER INC., SUN PHARMACEUTICAL INDUSTRIES LTD., MERCK KGAA, TAKEDA PHARMACEUTICAL COMPANY LIMITED, ASTRAZENECA, NOVARTIS AG, SANOFI, IRONWOOD PHARMACEUTICALS, INC., among others are the key market players.